Encorafenib patent expiry?

When does the encorafenib patent expire?

Encorafenib is the active ingredient in Braftovi (brand). Patent expiry depends on the specific country and on which patent family (compound, formulation, method-of-use, or combination) is being considered. The earliest expiry date is not the same as “when generics can launch” because market entry can also be delayed by secondary patents, patent litigation (including automatic “stay” periods), and regulatory exclusivities.

Why patent expiry isn’t the same as generic entry

Even after a primary patent expires, generics or biosimilar-style “follow-on” products may still be blocked if:
- other patents covering encorafenib (or its specific uses/combination regimens) are still in force, or
- courts delay entry following infringement challenges, or
- additional regulatory exclusivities apply in the relevant jurisdiction.

Which patents usually control encorafenib market exclusivity

For oncology small-molecule drugs like encorafenib, the remaining enforceable rights often come from secondary patent types such as:
- new formulations or manufacturing processes,
- specific dosing regimens,
- method-of-use claims tied to particular combinations (for example, with other targeted therapies used in BRAF-mutant disease),
- and jurisdiction-specific continuation filings.

What to check to get the exact expiry date you need

To find the correct encorafenib patent expiry for your location, you generally need:
- the jurisdiction (US, EU, UK, etc.),
- the marketing authorization holder (so you pull the right patent list tied to that product),
- the patent publication numbers (not just the drug name),
- and whether you care about “last patent expiry” or “first possible generic launch” after exclusivity and litigation effects.

If you tell me the country (and whether you mean Braftovi tablets/capsules or a specific encorafenib combination), I can narrow to the specific patent families and the likely earliest and latest relevant dates.

Are there different timelines for the US vs Europe?

Yes. Patent terms and calculation rules differ by jurisdiction, and Europe also has a system of supplementary protection certificates (SPCs) that can extend effective patent life beyond the original filing term. The US has its own mechanisms (including Patent Term Adjustments/Extensions and exclusivity periods), so dates can differ meaningfully even when the underlying compound patent is the same.

How litigation and “automatic stays” can shift the practical launch date

In markets where “patent challenge” processes apply (notably the US), the date generics can market the drug can be pushed out even after certain patents expire, because court schedules and statutory stay provisions can keep the branded product protected longer in practice.

Key missing detail: which encorafenib product and country?

“Encorafenib patent expiry” is not a single date. It varies by:
- country,
- product (brand and formulation),
- and which specific patent(s) you’re tracking.

Reply with the jurisdiction you care about (for example, US or EU) and the product name you’re referencing (typically Braftovi), and I’ll tailor the expiry/entry timeline to that market.